{"id":"pembrolizumab-placebo-saline","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Adverse events attributable to underlying disease progression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saline placebo is an inert control substance used in clinical trials to establish baseline efficacy and safety of the active drug (pembrolizumab, a PD-1 inhibitor) through comparison. It contains no active pharmaceutical ingredient and serves only as a comparator arm in phase 3 trials.","oneSentence":"This is a saline placebo control with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:27.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in pembrolizumab phase 3 clinical trials"}]},"trialDetails":[{"nctId":"NCT06556563","phase":"PHASE3","title":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"NovoCure GmbH","startDate":"2025-02-03","conditions":"Glioblastoma","enrollment":741},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT03142334","phase":"PHASE3","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-06-09","conditions":"Renal Cell Carcinoma","enrollment":994},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT05116189","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-13","conditions":"Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms","enrollment":643},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT02362594","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-16","conditions":"Melanoma","enrollment":1019},{"nctId":"NCT03713593","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-31","conditions":"Carcinoma, Hepatocellular","enrollment":794},{"nctId":"NCT03040999","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-05","conditions":"Head and Neck Neoplasms","enrollment":804},{"nctId":"NCT03867084","phase":"PHASE3","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-28","conditions":"Hepatocellular Carcinoma","enrollment":959},{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT06305767","phase":"PHASE1, PHASE2","title":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-03-28","conditions":"Bladder Cancer","enrollment":230},{"nctId":"NCT04227509","phase":"PHASE2","title":"Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-06-04","conditions":"Nasopharyngeal Carcinoma","enrollment":53},{"nctId":"NCT03924869","phase":"PHASE3","title":"Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Non-Small Cell Lung Cancer","enrollment":448},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367},{"nctId":"NCT06947928","phase":"PHASE2, PHASE3","title":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"TuHURA Biosciences, Inc.","startDate":"2025-10","conditions":"Advanced Or Metastatic Merkel Cell Carcinoma","enrollment":118},{"nctId":"NCT03062358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-27","conditions":"Carcinoma, Hepatocellular","enrollment":453},{"nctId":"NCT05933577","phase":"PHASE3","title":"A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-07-19","conditions":"Melanoma","enrollment":1089},{"nctId":"NCT04725188","phase":"PHASE2","title":"Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-20","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":255},{"nctId":"NCT03834506","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":1030},{"nctId":"NCT03834493","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-28","conditions":"Prostatic Neoplasms","enrollment":1244},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT04746924","phase":"PHASE3","title":"A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-06-08","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":662},{"nctId":"NCT05608291","phase":"PHASE3","title":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-16","conditions":"Melanoma","enrollment":1564},{"nctId":"NCT03425643","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-24","conditions":"Non-small Cell Lung Cancer","enrollment":797},{"nctId":"NCT03553836","phase":"PHASE3","title":"Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Melanoma","enrollment":976},{"nctId":"NCT02819518","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-07-27","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":882},{"nctId":"NCT03515837","phase":"PHASE3","title":"Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-29","conditions":"Non-small Cell Lung Cancer","enrollment":492},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT03189719","phase":"PHASE3","title":"First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-07-25","conditions":"Esophageal Neoplasms","enrollment":749},{"nctId":"NCT04428333","phase":"PHASE3","title":"Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2020-08-12","conditions":"Neoplasms, Head and Neck","enrollment":117},{"nctId":"NCT02775435","phase":"PHASE3","title":"A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-09","conditions":"Non-small Cell Lung Cancer","enrollment":559},{"nctId":"NCT03875092","phase":"PHASE3","title":"A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-21","conditions":"Non-small Cell Lung Cancer","enrollment":125},{"nctId":"NCT02578680","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-15","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":616},{"nctId":"NCT06099418","phase":"PHASE2","title":"Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.","status":"WITHDRAWN","sponsor":"Nykode Therapeutics ASA","startDate":"2024-04-18","conditions":"HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer","enrollment":""},{"nctId":"NCT04907227","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-23","conditions":"Prostatic Neoplasms","enrollment":81},{"nctId":"NCT05163223","phase":"PHASE2","title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer","status":"TERMINATED","sponsor":"Aston Sci. Inc.","startDate":"2022-02-28","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT03950674","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-22","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":40},{"nctId":"NCT06146777","phase":"PHASE3","title":"Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-12-01","conditions":"Papillary Renal Cell Carcinoma","enrollment":468},{"nctId":"NCT03302234","phase":"PHASE3","title":"Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-12-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":568},{"nctId":"NCT05791097","phase":"PHASE3","title":"Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT05809895","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-15","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT02494583","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-31","conditions":"Gastric Adenocarcinoma","enrollment":763},{"nctId":"NCT03331562","phase":"PHASE2","title":"A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer","status":"COMPLETED","sponsor":"Translational Genomics Research Institute","startDate":"2017-12-27","conditions":"Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":24},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT03066778","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-05-02","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":453},{"nctId":"NCT02500121","phase":"PHASE2","title":"Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer","status":"COMPLETED","sponsor":"Matthew Galsky","startDate":"2015-11-11","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":108},{"nctId":"NCT02702401","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-26","conditions":"Hepatocellular Carcinoma","enrollment":413},{"nctId":"NCT02130466","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-29","conditions":"Melanoma, Solid Tumors","enrollment":184},{"nctId":"NCT03881111","phase":"PHASE3","title":"First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-21","conditions":"Esophageal Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pembrolizumab placebo (saline)","genericName":"Pembrolizumab placebo (saline)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a saline placebo control with no active pharmacological mechanism. Used for Control arm in pembrolizumab phase 3 clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}